HomeFrameworksQuality & Manufacturing21 CFR 211

Framework  Quality & Manufacturing

21 CFR 211

21 CFR Part 211 is the FDA regulation for current good manufacturing practice (cGMP) for finished pharmaceuticals, read together with Part 210.

It covers the organization and personnel, buildings and facilities, equipment, control of components and containers, production and process controls, packaging and labeling, holding and distribution, laboratory controls, records and reports, and returned or salvaged drug products.

Every FDA drug inspection is measured against it, and every Form 483 observation cites a section of it.

In writing, Part 211 requires written procedures for almost everything: production and process control, cleaning and maintenance, component receipt and testing, packaging and labeling operations, laboratory testing and stability, complaint handling, distribution, and returns.

It requires master production and control records and batch production records for every batch, written specifications, and an independent quality control unit with documented authority to approve or reject materials, procedures, and products. The 2026 FDA draft guidance on responding to Form 483 observations shows how seriously the agency treats the written record.

AI-compiled
Share
Sponsored
Policy  Acknowledgment  Proof
AcknowledgedSOP MFG-022 rev 11by name, on record
cGMP in Writingwith AllyMatter
Batch It the Modern WaySOPs your operators acknowledged before the batch, not after
01
Approve it, lock the version
Non-author approval, obsolete copies blocked
02
Every operator on record
Revision-bound, re-collected on change
03
Show the investigator who read what
From $29/mo, 20 editors, unlimited staff (published)

Who has to comply

Any manufacturer, packager, labeler, or holder of finished drug products (human or animal) for the US market, domestic or foreign, including contract manufacturers and testing laboratories. Active pharmaceutical ingredient makers follow the ICH Q7 guidance under the statutory cGMP requirement rather than Part 211 directly.

Compounding pharmacies and outsourcing facilities have their own provisions.

What the assessor asks to see

Quality unit organization and responsibilities; site master file or equivalent overview; written procedures across all subparts; master production and control records and executed batch records; specifications and certificates of analysis; laboratory control records, method validation, stability program, out-of-specification investigations; equipment qualification, calibration, and cleaning validation; process validation reports; change control and deviation records; CAPA system; complaint and field alert records; annual product quality reviews; training records; data integrity controls including audit trails and electronic records under Part 11; distribution and recall records; supplier qualification and audit reports.

Where the requirement sits: 211.22(d) written QC procedures; 211.25 training records; 211.100 written production and process control procedures; 211.180-211.198 records

What AllyMatter does here

Controls the written procedures and proves training/acknowledgment on them.

AllyMatter publishes this site.

Assessors

Who assesses 21 CFR 211

FDA investigators (government inspection). Foreign regulators under mutual recognition agreements and PIC/S-aligned authorities may inspect the same site for their own markets. (regulatory inspection).

No firm has claimed a 21 CFR 211 assessor listing yet. Claim yours →

Consultants

Who helps with 21 CFR 211

A very mature cGMP consultant ecosystem exists, including former FDA investigators and large quality consultancies. Consultants run mock inspections and gap assessments, write and remediate procedure sets, run data integrity and validation programs, train staff, and manage 483 and warning letter responses and consent decree remediation.

Firms that name this framework in their own material. Listings we have not verified yet come from public filings and partner lists. Each firm can confirm its own.

No firm has claimed a 21 CFR 211 consultant listing yet. Claim yours →

Software

Tools for 21 CFR 211

Tools that name this framework in their own material.

Related reading

  1. FDA publishes draft guidance on responding to Form 483 observations after a drug CGMP inspectionExplains FDA's 2026 expectations for the content and timing of a 483 response, including the management and quality-system role.Covington & Burling
  2. FDA issues guidance on responding to FDA Form 483sA second reading of the same draft guidance, with more on section 211.192 investigations and handling technical disagreement with investigators.Arnold & Porter
  3. Requirements for electronic records contained in 21 CFR 211Untangles which record and signature obligations come from Part 211 itself rather than from Part 11, a common source of confusion.Pharmaceutical Technology

Independent third-party explainers, chosen by hand. Not affiliated with this site and not paid placements. All links are nofollow.

Need a hand implementing it?

Find a Consultant for 21 CFR 211

Tell us what you need done and we will point you to firms that do this work. Your details go to a firm only when you choose it.

From the publisher

Run the Policy Side of 21 CFR 211 in AllyMatter

Approve the policies 21 CFR 211 asks for, keep every version, and record a named acknowledgment from each person who has to read them.

See how AllyMatter works From $29/mo, 20 editors, unlimited staff

About this data

Pages on this site are compiled with AI from two or more linked sources, rewritten in our words, and reviewed by people in stages. Each record shows its stage and date. Nothing here is legal, audit or tax advice, and policyandcompliance.com accepts no responsibility for errors or for decisions made on it. Read the source, then decide.
How we compile and verify →

Think something is wrong?

corrections@policyandcompliance.com
Tell us the page and what you found. We check it against the source and fix it.
Corrections log →

Want to advertise here?

ads@policyandcompliance.com
A primary ad and a secondary placement, flat fee. Buying one changes nothing else on the page.